Quick Answer
Beam Therapeutics Inc. reported Diluted EPS of $0.81 per share (loss) for fiscal year 2025.
Beam Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.81 | +82.3% |
| 2024 | -$4.58 | -166.3% |
| 2023 | -$1.72 | +58.4% |
| 2022 | -$4.13 | +28.4% |
| 2021 | -$5.77 | -37.7% |
| 2020 | -$4.19 | +70.2% |
| 2019 | -$14.05 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.10 | +6.0% | -10.0% |
| June 30, 2025 | -$1.00 | +9.9% | +19.4% |
| March 31, 2025 | -$1.24 | -2.5% | -6.0% |
| September 30, 2024 | -$1.17 | +4.1% | -5.4% |
| June 30, 2024 | -$1.11 | -2.8% | +8.3% |
| March 31, 2024 | -$1.21 | +9.0% | +0.8% |
| September 30, 2023 | -$1.22 | +21.8% | -13.0% |
| June 30, 2023 | -$1.08 | -5.9% | +18.8% |
- Beam Therapeutics Inc. showed an increase of +82.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Beam Therapeutics Inc.’s diluted eps has grown by 94.2% (from $14.05 per share (loss) to $0.81 per share (loss)).
- The most recent figure is from Beam Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: